[{"orgOrder":0,"company":"ProfoundBio","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"Rinatabart Sesutecan","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":1.8,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.8,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Genmab"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Acquisition","leadProduct":"Rinatabart Sesutecan","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":1.8,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.8,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Genmab"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Rinatabart Sesutecan","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Undisclosed"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Ally Bridge Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"Rinatabart Sesutecan","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Ally Bridge Group","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Ally Bridge Group"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"PRO1184","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Undisclosed"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"PRO1184","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Undisclosed"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Sequoia China","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Series A Financing","leadProduct":"PRO1184","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Sequoia China","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Sequoia China"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Licensing Agreement","leadProduct":"PRO1184","moa":"FOLR1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0.25,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Synaffix","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Synaffix"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PRO1107","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Undisclosed"},{"orgOrder":0,"company":"ProfoundBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"PRO1160","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProfoundBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProfoundBio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProfoundBio \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by ProfoundBio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Rina-S (rinatabart sesutecan) is an investigational FRα-targeted, Topo1 ADC, which is being evaluated for FR alpha-expressing ovarian cancer, endometrial cancer, primary peritoneal carcinoma.

                          Product Name : Rina-S

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          September 15, 2024

                          Lead Product(s) : Rinatabart Sesutecan

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The acquisition grants Genmab worldwide rights to three clinical candidates, including Rina-S (rinatabart sesutecan), an FRα-targeted ADC aimed at treating ovarian and endometrial cancer.

                          Product Name : Rina-S

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : $1,800.0 million

                          May 21, 2024

                          Lead Product(s) : Rinatabart Sesutecan

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Genmab

                          Deal Size : $1,800.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Genmab acquires worldwide rights to PRO1184 (rinatabart sesutecan) for treating FRα-expressing platinum-resistant ovarian cancer and two other clinical candidates.

                          Product Name : Rina-S

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : $1,800.0 million

                          April 03, 2024

                          Lead Product(s) : Rinatabart Sesutecan

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Genmab

                          Deal Size : $1,800.0 million

                          Deal Type : Acquisition

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The financing aims to support the development of ProfoundBio's PRO1184 (rinatabart sesutecan), which is a FRα-targeted ADC being developed for patients with ovarian and endometrial cancer.

                          Product Name : Rina-S

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          February 13, 2024

                          Lead Product(s) : Rinatabart Sesutecan

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Ally Bridge Group

                          Deal Size : $112.0 million

                          Deal Type : Series B Financing

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : PRO1107 is an ADC targeting PTK7, currently in trials for PTK7-expressing endometrial, ovarian, and triple-negative breast cancers.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 05, 2024

                          Lead Product(s) : PRO1107

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : PRO1160 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 09, 2023

                          Lead Product(s) : PRO1160

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : PRO1184 demonstrates robust anti-tumor activity, is an ADC comprising a folate receptor alpha-directed antibody conjugated to the exatecan payload with ProfoundBio's novel, proprietary hydrophilic linker.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          January 03, 2023

                          Lead Product(s) : PRO1184

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : PRO1184 is an antibody-drug conjugate comprising a folate receptor alpha (FRa) directed antibody conjugated to an exatecan payload with a novel, proprietary hydrophilic linker.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          August 03, 2022

                          Lead Product(s) : PRO1184

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : ProfoundBio will use the proceeds to advance PRO1184 and PRO1160 into Phase 1 clinical trials. PRO1184 is a folate receptor alpha directed ADC for potential treatment of multiple solid tumors and PRO1160 is CD70-directed ADC for both hematological and so...

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          June 02, 2022

                          Lead Product(s) : PRO1184

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Sequoia China

                          Deal Size : $70.0 million

                          Deal Type : Series A Financing

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The deal provides access to multiple novel linker-payload technologies developed by Synaffix and includes access to the GlycoConnect™ glycan conjugation and HydraSpace™ polar spacer technologies.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          July 22, 2021

                          Lead Product(s) : PRO1184

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Synaffix

                          Deal Size : $246.0 million

                          Deal Type : Licensing Agreement

                          blank